Ubrogepant (Ubrelvy) is available as U50 and U100 tablets indicating the strength of the tablets (50 mg and 100 mg respectively.

Ubrogepant (Ubrelvy) Uses:

• An acute attack of Migraine:

  • It is recommended for the quick relief of adult migraines with or without aura.
  • It is not recommended for migraine prophylaxis.

Complete prescribing information of Ubrogepant (Ubrelvy) can be accessed here (PDF format)

Ubrogepant dose in adults:

Ubrogepant (Ubrelvy) dose in the treatment of Acute attack of Migraine: 

• 50 to 100 mg orally as a single dose initially.
• Depending on the response and tolerability of the patient, the dose may be given once again after 2 hours or longer.
• The maximum dose is 200 mg per day.
• It has not been determined whether the medication is safe when used to treat 8 migraines or more each month.

Ubrogepant (Ubrelvy) Dosage adjustment for concomitant therapy:

• Strong CYP3A4 inhibitors like ketoconazole, itraconazole, and clarithromycin):

  • The use of Ubrogepant (Ubrelvy) is contraindicated in patients taking these medicines.

• Moderate CYP3A4 inhibitors like cyclosporine, ciprofloxacin, fluconazole, fluvoxamine, grapefruit juice, and verapamil):

  • 50 mg orally as a single dose.
  • Avoid the second dose within 24 hours.
  • The maximum dose in one day is 50 mg.

• Weak CYP3A4 inhibitor:

  • 50 mg orally as a single dose initially.
  • Depending on the response and tolerability of the patient, the dose may be repeated once after 2 hours or more.
  • The maximum dose in a day is 100 mg.

• Strong CYP3A4 inducer such as phenytoin, barbiturates, rifampin, and St. John's wort):

  • Avoid concurrent use.

• Weak and moderate CYP3A4 inducers:

  • 100 mg orally as a single dose initially.
  • The dose may be repeated once after 2 hours or more, based on the patients' response and tolerability.
  • The maximum dose is 200 mg per 24 hours.

• Breast cancer resistance protein and/ or P-glycoprotein only inhibitor such as quinidine, carvedilol, eltrombopag, and curcumin):

  • 50 mg orally as a single dose initially.
  • Depending on the response and tolerability of the patient, the dose may be given once again after 2 hours or longer.
  • The maximum dose in 24 hours is 100 mg.

Ubrogepant (Ubrelvy) use in Children:

The safety and efficacy of the drug in children has not been established.

Ubrogepant (Ubrelvy) Pregnany Risk Category: C

• Ubrogepant (Ubrelvy).In animal reproduction studies, fetal harm has been shown.

Use while breastfeeding

• It is unknown if the drug will be excreted into breastmilk.
• Manufacturers recommend weighing the benefits of treating lactating mothers and the risks of drug exposure for infants.

Ubrogepant (Ubrelvy) dose adjustment in kidney disease:

• CrCl >=30mL/minute

  • It is not necessary to adjust the dose.

• CrCl 15 to 29, mL/minute

  • 50mg as a single dose in the beginning
  • In accordance with tolerance and response, the dose can be repeated up to two hours later.
  • Maximum daily intake is 100 mg.

• CrCl 15mL/minute

  • These patients have not been able to study its use and it should be avoided.

Ubrogepant (Ubrelvy) dose adjustment in liver disease:

• Mild to moderate impairment (Child Puugh class A or B)

  • It is not necessary to adjust the dose.

• Severe impairment (Child Puugh class C).

  • 50 mg is taken as a single dose when it's first administered.
  • The patient's response and tolerance may dictate if the dose is repeated after 2 hours.
  • Maximum daily intake is 100 mg

Side Effects of Ubrogepant (Ubrelvy) Include:

• Central nervous system:

  • Drowsiness

• Gastrointestinal:

  • Nausea
  • Xerostomia

Contraindication to Ubrogepant (Ubrelvy) Include:

Avoid using strong CYP3A4 inhibitors in conjunction.

Warnings and precautions

• Hepatic impairment
  • In the case of significant liver impairment, a dose reduction is required.
• Renal impairment
  • A reduction of the dose is necessary in severe renal disease.
  • People suffering from end-stage kidney disease should avoid it

How to administer Ubrogepant (Ubrelvy)?

It is administered with or without food.

Mechanism of action of Ubrogepant (Ubrelvy):

It blocks the receptor for the calcitonin-related peptide.

The C-max and absorption

• When a high-fat meal is consumed, they can be delayed.

Protein-bound

• 87%

Metabolism

• It is primarily found in the liver hepatic via CYP3A4.

Half-life Elimination:

• The average time of taking the drug is between 5 and 7 hours. It takes time to get there

Peak serum concentration

• It takes approximately 1.5 hours.

Excretion

• 42% of the drug is excreted as unchanged in the feces
• 6% is excreted into the urine.

International Brands of Ubrogepant:

• Ubrelvy

Price of Ubrogepant (Ubrelvy) Tablets in the US:

Each 50 mg Tablet costs: $102.00

Each 100 mg tablet costs: $102.00

Ubrogepant Brand Names in Pakistan:

No Brands Available in Pakistan.